STT Weekend Thread 4th-5th Feb, page-171

STTCOMP IMU FA Long
Imugene Developing cancer immunotherapy drugs based on anti bodies
Market cap $32.5 m
SOI 2.17 billion
Options on issue 371,166,262 expiry 31 Mar 2017
12 month price range .7c - 2.1 c
Cash $3.82 million
Catalyst
Imunotherapy is the treatment of cancer with substances or drugs that stimulate the patients immune response known as active immunisation
Gastric cancer trials timetable
Q 1 2017 Patients enrolled
Q1 - Q2 2017 Early patient data available.
Near term price has been increasing since drop after quarterly account, increased volume and rumours of deals etc.
Options expiry in March so maybe a pump to get converted.